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A B S T R A C T
Severe pulmonary hypertension is a progressive disease which leads to limitations of functional status and poor sur-
vival. We evaluated efficacy and safety of a short (3 months) and a long term (12 months) sildenafil treatment in patients
with severe pulmonary hypertension. We treated 12 patients with pulmonary hypertension with oral sildenafil. Patients
were followed at three time points, at baseline, and after 3 and 12 months of treatment. Primary end point was improve-
ment in functional exercise capacity assesed by 6-minute walk test, and secondary end points were changes in right ven-
tricle hemodynamics. We found significant improvement in 6-minute walk test distance from 357±193 m at baseline to
431±179 m after three months and further improvement to 501±159 m after 12 months (p<0.01); decrease in right ven-
tricule pressure from 107±42 mmHg at baseline to 87±32 mmHg after 12 months (p<0.01); and, decrease in right ven-
tricule diameter from 3.2±1.1cm to 2.76±0.86 cm after twelve months (p<0.01). Drug-related adverse events were mild
and transient in our group of patients. Long term (12 months) sildenafil treatment is effective and safe in our patients
with idiopathic and chronic thrombo-embolic pulmonary hypertension.
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Introduction
Severe pulmonary hypertension is a disease which
leads to severe limitations of functional status and poor
survival. Clinical features include progressive dyspnea
and exertion limitation. Pulmonary arterial hyperten-
sion is characterized by elevation of pulmonary vascular
resistance and consequently elevation in pulmonary ar-
tery pressure. This can lead to the right heart failure and
death1. Three factors contribute to increase in pulmo-
nary vascular resistance: vasoconstriction, small pulmo-
nary vessel remodeling and thrombosis in situ2. Abnor-
malities in mediator pathways contribute to pathogenesis
of pulmonary arterial hypertension. These include insuf-
ficient production of vasodilators like nitric oxide (NO)
and prostanoids, as well as increased production of vaso-
constrictors like endothelin, thromboxanes and seroto-
nin3–8. Advances in understanding molecular mechani-
sms suggest that endothelial dysfunction plays a key role
in pathogenesis of pulmonary hypertension2,3,6.
The current, most used conventional therapeutic mo-
dalities like diuretics, digoxin, oral anticoagulants and
calcium channel blockers are limited and unsatisfactory9–11.
Therefore, novel therapeutic agents like prostanoids (epo-
prostenol, beraprost, iloprost) and endtohelin-receptor
antagonists (bosentan) are recently approved12–18.
One of the new targeted molecules are phosphodi-
esterases. Phosphodiesterases (PDE) are superfamily of
enzymes that inactivate cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate (cGMP),
the second messengers of prostacyclin and NO. The pho-
phodiesterases have different tissue distribution and sub-
strate affinities19. The major cGMP degrading phospho-
diesterase, PDE-5, is abundantly expressed in lung ti-
ssue20. Inhibition of PDE-5 could augment and prolong
prostanoid and NO related vasodilator effects21–24. The
selective PDE-5 inhibitor sildenafil was approved for
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treatment of erectile disfunction. Sildenafil causes only
minor systemic effects in healthy humans25. Data from
experimental model of pulmonary hypertension showed
that sildenafil is a potent pulmonary vasodilator23. First
data of sildenafil efficacy in treatment of pulmonary hy-
pertension were reported as case reports26,27,28. Since
then, several reports on small number of patients sug-
gest efficacy of sildenafil treatment in patients with pul-
monary arterial hypertension, alone or in combination
with prostanoids or NO29–34. Most of these reports sho-
wed a short term (3 months) sildenafil efficacy. Two re-
ports showed a prolonged benefit of 5 and 6 months
sildenafil treatment as adjunct therapy32,34 and one small
series in patients with non-operable chronic thrombo-
embolic pulmonary hypertension showed efficacy of 12-
-months oral sildenafil treatment alone36. Only one, large,
double-blind, placebo-controlled study showed prolonged
sildenafil efficacy in patients with pulmonary hyperten-
sion37. Recent studies suggested that sildenafil may also
have direct anti-hypertrophic effect in cardiac muscle38,39.
In this study, we tried to estimate efficacy and safety
of a short (3 months) and a long term (12 months) treat-
ment with oral sildenafil in patients with severe pulmo-
nary hypertension. Primary end point of the study was
improvement in functional capacity measured with six-
-minute walking test, and secondary end points were de-




Patients with pulmonary arterial hypertension (PAH)
attending University Hospital for lung diseases »Jor-
danovac« during 2004 were considered for the study. Pa-
tients with idiopathic pulmonary hypertension, chronic
thrombo-embolic pulmonary hypertension who are not
suitable for surgical treatment and patients with pulmo-
nary hypertension due to non – corrected congenital car-
diac shunt were eligible for the study (40). The PAH diag-
nosis was based on right heart catheter mean pulmonary
artery pressure at rest over 25 mmHg. All patients were
symptomatic despite their conventional diuretic, digoxin
and anticoagulant therapy. None of the patients received
calcium-channel blockers. Eight patients showed irre-
versibility of pulmonary hypertension to prostanoids.
Four patients who showed reversibility to prostanoids
could not tolerate calcium-channel blockers. Study medi-
cation was added to patients’ conventional therapy. Ex-
clusion criteria included previous sildenafil treatment
and six-minute walking distance at the inclusion less
then 200 meters.
The study was done according to 1983 Declaration of
Helsinki and according good clinical practice. This study
was approved by the University Hospital for Lung Dis-
eases »Jordanovac« Ethics Committee and all patients
gave written informed consent before entering the study.
Study design
The study was non-sponsored, open-labeled and un-
controlled. All patients received during the first week
12.5 mg of oral sildenafil three times a day. Dose was
then up-titrated to 50 mg of sildenafil three times a day if
no systemic hypotension or other side-effects occurred.
Patients were followed in three time points: at baseline,
after three months and after 12 months of therapy.
Sildenafil treatment efficacy was estimated after first
three months of treatment and patients with improve-
ment in functional capacity were eligible for continua-
tion of sildenafil treatment.
Outcome measures
Before entering the study in all patients was per-
formed: the right heart catheterization, perfusion and
ventilation lung scan and pulmonary angiography. Dur-
ing the right heart catheterization the right heart and
pulmonary artery pressure were measured, pulmonary
vascular resistance and cardiac index were calculated,
and reversibility test was performed. Reversibility of pul-
monary hypertension was tested with iloprost. If there
was decrease in systolic pulmonary artery pressure for
more than 25% or pulmonary vascular resistance for 30%
or increase in systemic arterial oxygen saturation, pul-
monary hypertension was declared reversible.
The following parameters were analyzed at baseline
and at each time point: NYHA functional class, Borg
scale at rest and after 6-minute walk test (41), 6-minute
walking distance (42,43), right ventricle pressure (RVP)
and right ventricle diameter (RVD) estimated by trans-
thoracic echocardiography, blood gas analysis at rest and
after walking test, lung function and carbon dioxide dif-
fusion.
Statistical analysis
All variables were tested for normal distribution with
Kolmogorov-Smironov’s test. For variables with normal
distribution ANOVA for repeated measurement test was
performed, and a value of p<0.05 was considered signifi-
cant. For variables which showed a significant improve-
ment between baseline and at the end of follow-up pe-
riod, Scheffe’s post hoc test was performed. P value less
than 0.05 was found statistically significant.
Results
We included 12 patients in the study. Base-line pa-
tients’ characteristics are shown in Table 1. Five patients
with idiopathic pulmonary hypertension (IPH) (4 fe-
males, 1 male, average age 36.8 years, range from 22–52);
five patients with chronic thrombo-embolic pulmonary
hypertension (CTEPH) (3 females, 2 males, average age
46; range from 36–57) and two males with Eisenmenger’
syndrome (average age 39 years; range 30–48). All pa-
tients had severe pulmonary hypertension. Mean pulmo-
nary artery pressure measured during right heart cathe-
terization was 53±15 mmHg (range from 37 to 68 mmHg).
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At the time of the inclusion patients were NYHA class III
and IV, most of them NYHA III. All patients were suc-
cessfully titrated to dose of 50 mg three times a day dur-
ing first two weeks of treatment.
At the first time point, after three months, in two pa-
tients with Eisenmenger’ syndrome there was a decrease
in 6-minute walk test distance from 200±20 m to 165±45
m. We also noticed in these two patients increase in Borg
dyspnea score for average 1.5 units, NYHA class re-
mained the same, as well as right ventricle pressure.
These two patients were excluded after three months.
Functional capacity
The mean 6-minute walk distance increased for 74 m af-
ter three months (from 357±193 m at baseline to 431±179
m after three months, p<0.01, and further increased by
70 m (to 501±159 m after 12 months of sildenafil treat-
ment, p<0.01). Overall improvement was 144 m after
twelve months (p<0.01) (Figure 1). Borg dyspnea scores
at rest and after exertion improved for an average one
point. This improvement was not statistically significant.
Patients NYHA functional status improved for one class
in average.
Right ventricle pressure
Right ventricle pressure (RVP) decreased by 12 mmHg
after three months (from 107±42 to 95±40 mmHg; p<0.01)
and further decreased for 8 mmHg after twelve months
of treatment (to 87±32 mmHg; p<0.01). In total, after
twelve months of treatment we noticed decrease for 20
mmHg (p<0.01) (Figure 2).
Right ventricle diameter
After three months of treatment right ventricle diam-
eter (RVD) decreased for average 0.3 cm (from 3.2±1.1
cm to 2.9±0.9 cm; p<0.05), and then further for another
0.14 cm (to 2.76±0.86 cm; p<0.05). In total, after 12
months of treatment RVD decreased by 0.44 cm (p<0.01)
(Figure 3).
Arterial blood gas analyses and safety
In all 10 patients who completed the study we notice
slightly improvement in PaO2 at rest and after exertion.
However, this improvement was not statistically signifi-
cant. There were no changes in lung capacity for carbon
monoxide diffusion.
During the study we notice only minor side effects.
One patient complaint for headache during first months
of treatment; one patient had muscle pain in the last two






Age in years, mean (range) 40.7 (22–57)





6-min walk distance, m 357 ± 153
Dyspnea score (Borg index) 3.9 ± 1.6
Hemodynamic variables
RA pressure, mmHg 8.9 ± 4
PAP
systolic, mmHg 86 ± 36
diastolic, mmHg 31 ± 24
mPAP, mmHg 53 ± 15
PVR, din sec cm–5 718.4 ± 275.6
Cardiac index, L min–1 m–2 2.41 ± 0.43
RV pressure, mmHg 107 ± 42
RV diameter, cm 3.2 ± 1.1
Reversibility to prostanoids Yes/No 4:8
CTEPH = chronic thrombo – embolic pulmonary hypertension;
PAP = pulmonary artery pressure; RA = right atrium; mPAP =
mean pulmonary artery pressure; PVR = pulmonary vascular
resistance; RV = right ventricule.
RA, PAP, mPAP, CI and PVR were estimated during right heart
















Fig. 1. Change in 6 – minute walk test distance from baseline
















Fig. 2. Change in right ventricle pressure from baseline to three
and twelve months of sildenafil treatment (each line represent one
patient).
months of the study. There were no withdrawals during
the study caused by drug – related adverse events.
Discussion
Most of the clinical trials use functional capacity test-
ing measured by a 6-minute walking test as primary end
point12–18,30–32,36,37,39. Six-minute walk distance commonly
used in clinical trials for the assessment of exercise ca-
pacity and as independent predictor of mortality44.
In this small, open study, sildenafil significantly im-
proved functional capacity measured by 6-minute walk
test, after three and then further after twelve months of
treatment. Increase in 6-minute walk distance noticed in
this study was significantly better than increase noticed
in SUPER trial (74 m to 48 after three months, and 144
m to 51 m after twelve months, p<0.001 for all compari-
sons)37. The much higher improvement in our study is
most likely the result of small number of patients. In
SERAPH study improvement in 6-minute walk distance
was similar to our findings (114 m after 16 weeks of
sildenafil treatment39). The most important observation
in our study is sustained and prolonged benefit of sil-
denafil treatment. However, Galie et al. in SUPER trial
did not found significant improvement in functional ca-
pacity between months three and twelve37. Similar find-
ing was showed in study by Barst et al. The early im-
provement in 6-minute walk distance was lost after six
months of beraprost therapy45. On the contrary, in our
study 6-minute walk distance significantly improved be-
tween months three and twelve by another 70 m.
Consistent and significant improvement during twelve
months sildenafil treatment period may suggest chronic
effects and additional benefits possibly via reversal of
pulmonary vascular remodeling. Improvement in NYHA
class and Borg score were noticed already after three
months and remained improved during the treatment
period. Our study showed that sildenafil significantly re-
duced right ventricle pressure already after three mon-
ths of treatment and there was further decrease noticed
after twelve months of treatment.
As a secondary end point we used improvement in
right ventricle diameter. To the best of our knowledge,
there was only one study so far which analyzed impact of
sildenafil treatment on right ventricle mass and volume39.
However, to simplify the procedure, we used echocardio-
graphy to estimate diameter of the right ventricle. And
indeed, we noticed significant decrease in right ventricle
dimension already after three months of treatment, and
then further decrease after twelve months of sildenafil
treatment. These results are similar to the results of the
SERAPH study which noticed significant reduction in
right ventricle mass measured by cardiac MR39.
So, part of our findings, improvement in a 6-minute
walk distance and in NYHA class could be explainable
with noticed improvement in right ventricle hemodyna-
mics. Improvement in these patients is not only explain-
able by improvement of resting hemodynamics or by
vasodilator effect of sildenafil29. Sildenafil also has anti –
proliferative and anti – remodeling effect, and these ef-
fects could explain further changes in hemodynamics be-
yond just vasodilator effect38,39. Unfortunately, at the
moment it is not known if this effect of reducing right
ventricle diameter had an impact on improvement in
functional capacity. There was no change in pO2 at rest
and after the exertion and in DLCO.
In two patients with Eisenmenger syndrome there
was no improvement in followed parameters. Neverthe-
less, in these patients we noticed deterioration in func-
tional capacity and in followed parameters, so sildenafil
treatment was discontinued after three months of the
therapy.
In all patients in our study sildenafil was well toler-
ated, only minor side effects during the study period oc-
curred (headache, muscle pain, nausea).
Some reports suggest additive effects of sildenafil
added to other drugs20,30,31,33,34 but further, larger, ran-
domized, double-blind, clinical trails are necessary to es-
tablish additive effects of sildenafil to other drugs used in
the therapy of pulmonary arterial hypertension. In our
study patients did not use calcium-channel blockers or
any other vasodilator so we were able to measure pure
sildenafil treatment effects which is different to other
published studies.
There are only few studies that estimated role of oral
sildenafil alone in treatment of pulmonary arterial hy-
pertension32,35–37,39 and our results are in favor of these
studies.
Data in present study showed no efficacy of sildenafil
treatment in patients with Eisenmenger syndrome, so
for these patients other treatment options should be con-
sidered, although only two patients in this group are in-
sufficient for any general conclusions.
Limitation of our study was a small number of pa-
tient, lack of power-analysis and lack of control group
(open-label design). An important observation from this
trial is that early beneficial effects of sildenafil are con-
sistent and further improved with prolonged use.






















Fig. 3. Change in right ventricle diameter from baseline to three
and twelve months of sildenafil treatment. (each line represent
one patient).
In conclusion, sildenafil significantly improved exer-
cise capacity and hemodynamics in our small group of pa-
tients with severe pulmonary hypertension (both idio-
pathic and CEPTH). In these patients, sildenafil could be
a reasonable option for the first line therapy46,47 but fur-
ther studies, on larger number of patients are needed to
confirm our findings. Efficacy of sildenafil treatment in
these patients was proportional to the duration of treat-
ment. However, further trials are necessary to determine
a position of sildenafil treatment in patients with pulmo-
nary arterial hypertension as monotherapy or in combi-
nation with prostanoids and/or endothelin-receptor an-
tagonists.
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U^INKOVITOST I SIGURNOST ORALNOG SILDENAFILA U BOLESNIKA
S TE[KOM PLU]NOM HIPERTENZIJOM
S A @ E T A K
Te{ka plu}na hipertenzija je bolest koja zna~ajno smanjuje funkcijski kapacitet bolesnika i ima lo{u prognozu. U
studiji smo ispitivali kratkoro~ni (3 mjeseca) i dugoro~ni (12 mjeseci) u~inak sildenafila u bolesnika s te{kom plu}nom
hipertenzijom. U studiju je bilo uklju~eno 12 bolesnika koji su pra}eni prije po~etka lije~enja, nakon 3 mjeseca te nakon
12 mjeseci lije~enja. Primarni cilj pra}enja je bilo pobolj{anje u 6-minutnom testu hoda, a sekundarni pad talka u
desnom ventrikulu. U bolesnika je do{lo do zna~ajnog pobolj{anja hodne pruge nakon 3 te nakon 12 mjeseci pra}enja.
Tako|er je do{lo do smanjenja tlaka u desnom ventrikulu nakon 3 te nakon 12 mjeseci pra}enja. Nisu zabilje`ene
zna~ajne nuspojave. U zaklju~ku, sildenafil je siguran i u~inkovit u lije~enju kroz 12 mjeseci u bolesnika s te{kom
idioptaskom plu}nom hipertnezijom, te plu}nom hipertenzijom uzrokovanom kroni~nim trombo-embolizmom.
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